Calcium/calmodulin-dependent kinase II regulates notch-1 signaling in prostate cancer cells

Journal of Cellular Biochemistry

Volumn 106, Issue 1, 2009, Pages 25-32

  Mamaeva, Olga A ^a   Kim, Junghyun ^a   Feng, Gong ^a   McDonald, Jay M ^a,b  

^a University of Alabama at Birmingham   (United States)

^b BIRMINGHAM VA MEDICAL CENTER   (United States)

Author keywords

secretase; c Myc; Calcium calmodulin dependent kinase II; Cancer; Hes 1; Notch 1; Prostate

Indexed keywords

CALCIUM; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; GAMMA SECRETASE; N [2 [[N [3 (4 CHLOROPHENYL) 2 PROPENYL] N METHYLAMINO]METHYL]PHENYL] N (2 HYDROXYETHYL) 4 METHOXYBENZENESULFONAMIDE; NOTCH1 RECEPTOR; TRANSCRIPTION FACTOR HES 1;

ARTICLE; BONE METASTASIS; CANCER CELL; CELL DAMAGE; CELL STRAIN LNCAP; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO SELECTION; OSTEOBLAST; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION;

AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; BENZYLAMINES; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE TYPE 2; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; MALE; MICE; MICE, NUDE; PROSTATIC NEOPLASMS; RECEPTOR, NOTCH1; SIGNAL TRANSDUCTION; SULFONAMIDES;

EID: 58649118681     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.21973     Document Type: Article

References (33)

1. Ang ES, Zhang P, Steer JH, Tan JW, Yip K, Zheng MH, Joyce DA, Xu J. 2007. Calcium/calmodulin-dependent kinase activity is required for efficient induction of osteoclast differentiation and bone resorption by receptor activator of nuclear factor kappa B ligand (RANKL). J Cell Physiol 212(3): 787-795.
2. Colbran RJ. 2004. Targeting of calcium/calmodulin-dependent protein kinaseII. Biochem J 378:1-16.
3. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA, Murphy GP. 1983. LNCaP model of human prostatic carcinoma. Cancer Res 43(4):1809-1818.
4. 2+/Calmodulin-Dependent Protein Kinase II: The role of structure and autoregulation in cellular function. Annu Rev Biochem 71:473-510.
5. Jarriault S, Brou C, Logeat F, Schroeter EH, Kopan R, Israel A. 1995. Signalling downstream of activated mammalian Notch. Nature 377:355-358.
6. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun J. 2007. Cancer statistics, 2007. CA Cancer J Clin 57:43-66.
7. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW. 1979. Establishment and characterization of human prostatic carcinoma cell line (PC-3). Invest Urol 17:16-23.
8. Kim S-K, Park H-J, Hong HS, Baik EJ, Jung MW, Mook-Jung I. 2005. ERK1/2 is an endogenous negative regulator of the γ-secretase activity. FASEB J 20:157-159.
9. Latil A, Vidaud D, Valeri A, Fournier G, Vidaud M, Lidereau R, Cussenot O, Bieche I. 2000. Hes-1 expression correlates with MYC overexpression in human prostate cancer. Int J Cancer 89:172-176.
10. Lin Dl, Tarnowski CP, Zhang J, Day J, Rohn E, Patel AH, Morris MD, Keller ET. 2001. Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro. Prostate 47:212-221.
11. Mori K, Le Goff B, Charrier C, Battaglia S, Heymann D, Redini F. 2007. DU145 human prostate cancer cells express functional receptor activator of NFkB: New insights in the prostate cancer bone metastasis process. Bone 40:981-990.
12. Niranjan T, Bielesz B, Gruenwald A, Ponda MP, Kopp JB, Thomas DB, Susztak K. 2008. The Notch pathway in podocytes plays a role in the development of glomerular disease. Nat Med 14(3):290-298.
13. Oswald F, Liptay S, Adler G, Schmid RM. 1998. NF-kappaB2 is a putative target gene of activated Notch-1 via RBP-Jkappa. Mol Cell Biol 18:2077-2088.
14. Palomer T, Lim WK, Odom DT, Sulis ML, Real PJ, Margolin A, Barnes KC, O'Neil J, Nueberg D, Weng AP, Aster JC, Sigaux F, Soulier J, Look AT, Yong RC, Califano A, Ferrando AA. 2006. Notch1 directly regulates c-Myc and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proc Natl Acad Sci 103(48):18261-18266.
15. Pear WS, Aster JC, Scott ML, Hasserjian RP, Soffer B, Sklar J, Baltimore D. 1996. Exclusive development of T cell neoplasms in mice transplanted with bone marrow expressing activated Notch alleles. J Exp Med 183:2283-2291.
16. Rizzo P, Miao H, D'Souza G, Osipo C, Yun J, Zhao H, Mascarenhas J, Wyatt D, Antico G, Hao L, Yao K, Rajan P, Hicks C, Siziopikou K, Selvaggi S, Bashir A, Bhandari D, Marchese A, Lendahl U, Qin J-Z, Tonetti DA, Albain K, Nickoloff BJ, Miele L. 2008. Cross-talk between Notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches. Cancer Res 68(13): 5226-5235.
17. Rodriguez-Mora OG, LaHair MM, Evans MJ, Kovacs CJ, Allison RR, Sibata CH, White KS, McCubrey JA, Franklin RA. 2006. Inhibition of the CaM-Kinases augments cell death in response to oxygen radicals and oxygen radical inducing cancer therapies in MCF-7 human breast cancer cells. Cancer Biol Ther 5(8):1022-1030.
18. Rokhlin OW, Taghiyev AF, Bayer KU, Bumcrot D, Koteliansk VE, Glover RA, Cohen MB. 2007. Calcium/Calmodulin-Dependent Kinase II plays an important role in prostate cancer cell survival. Cancer Biol Ther 6(5):732- 742.
19. Ronchini C, Capobianco AJ. 2001. Induction of cyclin D1 transcription and CDK2 activity by Notch (ic): Implication for cell cycle disruption in transformation by Notch (ic). Mol Cell Biol 21:5925-5934.
20. Roy M, Pear WS, Aster JC. 2007. The multifaceted role of Notch in cancer. Curr Opin Genet Dev 17:52-59.
21. Seales EC, Micoli KJ, McDonald JM. 2006. Calmodulin is a critical regulator of osteoclastic differentiation, function, and survival. J Cell Biochem 97: 45-55.
22. Srinivasan M, Edman CF, Schulman H. 1994. Alternative splicing introduces a nuclear localization signal that targets multifunctional CaM Kinase to the nucleus. J Cell Biochem 126(4):839-852.
23. Stone KR, Mickey DD, Wunderli H, Mickey GH, Paulson DF. 1978. Isolation of a human prostate carcinoma cell line (DU 145). Int J Cancer 21(3):274-281.
24. Thalmann GN, Anezinis PE, Chang SM, Zhau HE, Kim EE, Hopwood VL, Pathak S, von Eschenbach AC, Chung LW. 1994. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res 54:2577-2581.
25. Tombes RM, Krystal GW. 1997. Identification of novel human tumor cell- specific CaMKII variants. Biochim Biophys Acta 1355:281-292.
26. Wang Z, Banerjee S, Li Y, Rahman KMW, Zhang Y, Sarkar F. 2006. Dawn- regulation of Notch-1 inhibits invasion by inactivation of nuclear factor-κB, Vascular endothelial growth factor, and matrix metalloproteinase-9 in pancreatic cancer cells. Cancer Res 66(5):2778-2784.
27. Weng AP, Millholland JM, Yashiro-Ohtani Y, Arcangeli ML, Lau A, Wai C, del Blanco C, Rodriguez CG, Sai H, Tobias J, Li Y, Wolf MS, Shachaf C, Felsher D,
28. Blacklow Sc, Pear WS, Aster JC. 2006. c-Myc is an important direct target of Notch-1 in T-cell acute lymphoblastic leukemia/lymphoma. Genes Dev 20:2096-2109.
29. Wu F, Stutzman A, Mo Y-Y. 2007. Notch signaling and its role in breast cancer. Front Biosci 12:4370-4383.
30. Yuan K, Chung LWK, Siegal GP, Zayzafoon M. 2007. α-CaMKII controls the growth of human osteosarcoma by regulating cell cycle progression. Lab Invest 87:938-950.
31. Zayzafoon M. 2006. Calcium/Calmodulin signaling controls osteoblast growth and differentiation. J Cell Biochem 97:56-70.
32. Zayzafoon M, Abdulkadir SA, McDonald JM. 2004. Notch signaling and ERK activation are important for the osteomimetic propreties of prostate cancer bone metastatic cell lines. J Biol Chem 279(5):3662-3670.
33. Zayzafoon M, Fulzele K, McDonald JM. 2005. Calmodulin and Calmodulin- dependent Kinase IIα regulate osteoblast differentiation by controlling c-fos expression. J Cell Biochem 280(8):7049-7059.